COVID-19

Pharmacy Times® interviewed Sue Peschin, president and CEO of Alliance for Aging Research, on the work that the COVID-19 Vaccine Education and Equity Project is doing to support education about and equitable access to COVID-19 vaccines.

The additional doses bring the EC’s confirmed order commitment to 160 million doses, which will commence from the company’s dedicated European supply chain.

The COVID-19 pandemic has accelerated both acceptance and payment of novel care delivery models including telehealth.

Pharmacists can now play a larger role in increasing vaccination rates, while pharmacies can continue to be safe and convenient settings in which patients can receive vaccines.

If granted an EUA by the FDA, mRNA-1273 would become the second COVID-19 vaccine to receive the designation.

Pharmacists, physicians, and nurses have been among the first to receive COVID-19 vaccinations at health care facilities across the country.

Pfizer’s COVID-19 vaccine vials are supposed to hold 5 doses, but using a sixth or seventh dose could expand the supply by up to 40%.

Pharmacy Times® interviewed John Beckner, the senior director of strategic initiatives at the National Community Pharmacists Association, on how pharmacists can help people come back for the second dose of the COVID-19 vaccine.

Pharmacy Times® interviewed John Beckner, the senior director of strategic initiatives at the National Community Pharmacists Association, on some of the challenges community pharmacies may need to manage when receiving and administering COVID-19 vaccines.

Pharmacy Times® interviewed John Beckner, the senior director of strategic initiatives at the National Community Pharmacists Association, on the work needed to prepare for the arrival and administration of COVID-19 vaccines.

Results of Ellume’s rapid at-home COVID-19 test are sent to a smartphone in 15 minutes or less.

There are many benefits to adopting and integrating new technological methods for hosting pharmacy organization events.

Tips and tricks to make mask-wearing less problematic during the COVID-19 pandemic.

Although cytokine storms are usually associated with severe COVID-19, study indicates less severe disease may also be at risk of cytokine storm.

A thorough understanding of immunization billing processes for Medicare, Medicaid, and other third-party payers will be critical to ensure pharmacy staff can efficiently serve their communities and facilitate a smooth reimbursement process.

Among a subset of participants in the COVID-19 vaccine clinical trials, 0.63% of individuals in the vaccinated group had hypersensitivity-related adverse events that may represent allergic reactions.

Under the 340B Prime Vendor Program, the Prime Vendor has several functions that it carries out to support stakeholders in operating and navigate the field so that they can effectively achieve lower 340B drug pricing for those who need it most.

The FDA is expected to review the safety and efficacy data package from Moderna's COVID-19 vaccine candidate on December 17, which could lead to an EUA being issued this week.

As administration of COVID-19 begins, pharmacies are preparing to vaccinate millions of people, not only once but twice.

Learn how you and your staff can help patients differentiate between common cough/cold symptoms and COVID-19 while also offering additional educational resources.

Pharmacy Times® interviewed Signe Pringle, the assistant secretary for the Maryland Department of Commerce, on a signed partnership between Quebec and Maryland to foster collaboration around health science research during COVID-19 and beyond.

This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.

Delirium is a common syndrome experienced by patients with COVID-19 while being treated in the ICU, according to a session at the 2020 ASHP Midyear Clinical Meeting and Exhibition.

The COVID-19 pandemic has shed light on the need to further expand the accessible, trusted care provided by community pharmacies.

Distribution of the first 2.9 million doses of the COVID--19 vaccine jointly developed by Pfizer and BioNTech are expected to begin within hours of the FDA’s decision.